Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Malignant Melanoma

Free Subscription Articles published in Nat Med Retrieve available abstracts of 47 articles: HTML format

Single Articles

May 2021
1. LIU D, Lin JR, Robitschek EJ, Kasumova GG, et al
   Evolution of delayed resistance to immunotherapy in a melanoma responder.
   Nat Med. 2021 May 3. pii: 10.1038/s41591-021-01331.
   PubMed     Abstract available
   
   
   February 2021
2. MENZIES AM, Amaria RN, Rozeman EA, Huang AC, et al
   Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
   Nat Med. 2021 Feb 8. pii: 10.1038/s41591-020-01188.
   PubMed     Abstract available
   
   
   
3. ROZEMAN EA, Hoefsmit EP, Reijers ILM, Saw RPM, et al
   Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
   Nat Med. 2021 Feb 8. pii: 10.1038/s41591-020-01211.
   PubMed     Abstract available
   
   
   January 2021
4. PEREZ-GUIJARRO E, Yang HH, Araya RE, El Meskini R, et al
   Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
   Nat Med. 2021 Jan 29. pii: 10.1038/s41591-021-01252.
   PubMed    
   
   
   
5. HU Z, Leet DE, Allesoe RL, Oliveira G, et al
   Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
   Nat Med. 2021 Jan 21. pii: 10.1038/s41591-020-01206.
   PubMed     Abstract available
   
   
   
6. STOWER H
   Microbiome transplant-induced response to immunotherapy.
   Nat Med. 2021;27:21.
   PubMed    
   
   
   
7. YU J, Green MD, Li S, Sun Y, et al
   Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.
   Nat Med. 2021;27:152-164.
   PubMed     Abstract available
   
   
   October 2020
8. CEREZO-WALLIS D, Contreras-Alcalde M, Troule K, Catena X, et al
   Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state.
   Nat Med. 2020 Oct 19. pii: 10.1038/s41591-020-1073.
   PubMed     Abstract available
   
   
   
9. DUMMER R, Lebbe C, Atkinson V, Mandala M, et al
   Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
   Nat Med. 2020;26:1557-1563.
   PubMed     Abstract available
   
   
   
10. ALGAZI AP, Othus M, Daud AI, Lo RS, et al
    Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
    Nat Med. 2020;26:1564-1568.
    PubMed     Abstract available
    
    
    
11. RYLL B
    From good to great: what patients can do for your medical research.
    Nat Med. 2020;26:1508.
    PubMed    
    
    
    July 2020
12. ALLEN BM, Hiam KJ, Burnett CE, Venida A, et al
    Systemic dysfunction and plasticity of the immune macroenvironment in cancer models.
    Nat Med. 2020;26:1125-1134.
    PubMed     Abstract available
    
    
    June 2020
13. LIU D, Schilling B, Liu D, Sucker A, et al
    Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
    Nat Med. 2020 Jun 19. pii: 10.1038/s41591-020-0975.
    PubMed     Abstract available
    
    
    
14. LIU Y, Jain A, Eng C, Way DH, et al
    A deep learning system for differential diagnosis of skin diseases.
    Nat Med. 2020;26:900-908.
    PubMed     Abstract available
    
    
    May 2020
15. OSTENDORF BN, Bilanovic J, Adaku N, Tafreshian KN, et al
    Common germline variants of the human APOE gene modulate melanoma progression and survival.
    Nat Med. 2020 May 25. pii: 10.1038/s41591-020-0879.
    PubMed     Abstract available
    
    
    April 2020
16. PEREZ-GUIJARRO E, Yang HH, Araya RE, El Meskini R, et al
    Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
    Nat Med. 2020 Apr 13. pii: 10.1038/s41591-020-0818.
    PubMed     Abstract available
    
    
    March 2020
17. TADROS AR, Romanyuk A, Miller IC, Santiago A, et al
    STAR particles for enhanced topical drug and vaccine delivery.
    Nat Med. 2020;26:341-347.
    PubMed     Abstract available
    
    
    February 2020
18. FAIRFAX BP, Taylor CA, Watson RA, Nassiri I, et al
    Peripheral CD8(+) T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.
    Nat Med. 2020;26:193-199.
    PubMed     Abstract available
    
    
    December 2019
19. AUSLANDER N, Lee JS, Ruppin E
    Reply to: 'IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma'.
    Nat Med. 2019;25:1836-1838.
    PubMed    
    
    
    
20. CARTER JA, Gilbo P, Atwal GS
    IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma.
    Nat Med. 2019;25:1833-1835.
    PubMed    
    
    
    
21. LIU D, Schilling B, Liu D, Sucker A, et al
    Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
    Nat Med. 2019;25:1916-1927.
    PubMed     Abstract available
    
    
    July 2019
22. RIBAS A, Lawrence D, Atkinson V, Agarwal S, et al
    Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Nat Med. 2019 Jul 2. pii: 10.1038/s41591-019-0535.
    PubMed     Abstract available
    
    
    June 2019
23. RIBAS A, Lawrence D, Atkinson V, Agarwal S, et al
    Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0476.
    PubMed     Abstract available
    
    
    
24. ASCIERTO PA, Ferrucci PF, Fisher R, Del Vecchio M, et al
    Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0448.
    PubMed     Abstract available
    
    
    
25. ROZEMAN EA, Blank CU
    Combining checkpoint inhibition and targeted therapy in melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0482.
    PubMed    
    
    
    
26. SULLIVAN RJ, Hamid O, Gonzalez R, Infante JR, et al
    Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0474.
    PubMed     Abstract available
    
    
    May 2019
27. ZAPPASODI R, Sirard C, Li Y, Budhu S, et al
    Rational design of anti-GITR-based combination immunotherapy.
    Nat Med. 2019;25:759-766.
    PubMed     Abstract available
    
    
    March 2019
28. NEWMAN S, Fan L, Pribnow A, Silkov A, et al
    Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas.
    Nat Med. 2019 Mar 4. pii: 10.1038/s41591-019-0373.
    PubMed     Abstract available
    
    
    
29. LONG GV
    Making a difference to many.
    Nat Med. 2019;25:356.
    PubMed    
    
    
    
30. TURAJLIC S
    Standing on the shoulders of giants.
    Nat Med. 2019;25:357.
    PubMed    
    
    
    February 2019
31. HUANG AC, Orlowski RJ, Xu X, Mick R, et al
    A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
    Nat Med. 2019 Feb 25. pii: 10.1038/s41591-019-0357.
    PubMed     Abstract available
    
    
    December 2018
32. TRUCCO LD, Mundra PA, Hogan K, Garcia-Martinez P, et al
    Publisher Correction: Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
    Nat Med. 2018 Dec 18. pii: 10.1038/s41591-018-0325.
    PubMed     Abstract available
    
    
    
33. TRUCCO LD, Mundra PA, Hogan K, Garcia-Martinez P, et al
    Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
    Nat Med. 2018 Dec 3. pii: 10.1038/s41591-018-0265.
    PubMed     Abstract available
    
    
    November 2018
34. ROBERT C
    Is earlier better for melanoma checkpoint blockade?
    Nat Med. 2018;24:1645-1648.
    PubMed     Abstract available
    
    
    October 2018
35. CEREZO M, Guemiri R, Druillennec S, Girault I, et al
    Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
    Nat Med. 2018 Oct 29. pii: 10.1038/s41591-018-0217.
    PubMed     Abstract available
    
    
    
36. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0252.
    PubMed     Abstract available
    
    
    
37. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0251.
    PubMed     Abstract available
    
    
    
38. AUSLANDER N, Zhang G, Lee JS, Frederick DT, et al
    Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Nat Med. 2018 Oct 17. pii: 10.1038/s41591-018-0247.
    PubMed     Abstract available
    
    
    
39. BLANK CU, Rozeman EA, Fanchi LF, Sikorska K, et al
    Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
    Nat Med. 2018 Oct 8. pii: 10.1038/s41591-018-0198.
    PubMed     Abstract available
    
    
    
40. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 8. pii: 10.1038/s41591-018-0197.
    PubMed     Abstract available
    
    
    August 2018
41. AUSLANDER N, Zhang G, Lee JS, Frederick DT, et al
    Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Nat Med. 2018 Aug 20. pii: 10.1038/s41591-018-0157.
    PubMed     Abstract available
    
    
    January 2018
42. BOSHUIZEN J, Koopman LA, Krijgsman O, Shahrabi A, et al
    Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
    Nat Med. 2018 Jan 15. pii: nm.4472. doi: 10.1038/nm.4472.
    PubMed     Abstract available
    
    
    October 2017
43. MURGAI M, Ju W, Eason M, Kline J, et al
    KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis.
    Nat Med. 2017;23:1176-1190.
    PubMed     Abstract available
    
    
    August 2017
44. XUE Y, Martelotto L, Baslan T, Vides A, et al
    An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
    Nat Med. 2017;23:929-937.
    PubMed     Abstract available
    
    
    July 2017
45. MAYORCA-GUILIANI AE, Madsen CD, Cox TR, Horton ER, et al
    ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix.
    Nat Med. 2017;23:890-898.
    PubMed     Abstract available
    
    
    December 2016
46. PEINADO H, Alec kovic M, Lavotshkin S, Matei I, et al
    Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
    Nat Med. 2016;22:1502.
    PubMed    
    
    
    October 2016
47. LINNEMANN C, van Buuren MM, Bies L, Verdegaal EM, et al
    Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.
    Nat Med. 2016;22:1192.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: